TheraCell Announces First Surgical Use Of TheraFuze DBF® Fiber Bullets™ In An Interbody TLIF Cage
TheraCell completes first surgical case with the TheraFuze DBF® Fiber Bullets™ offering surgeons an improved solution for allograft delivery in MIS surgeries
News provided by
Share this article
Share this article
LOS ANGELES, Dec. 30, 2020 /PRNewswire/ TheraCell Inc., a leading allograft solution company, today announced that it has completed the first surgical case using its TheraFuze DBF® Fiber Bullets™. This unique DBF fiber form is designed for minimal access delivery into expandable cages, revisions and other surgical applications.
The lyophilized Fiber Bullets™ can be dispensed using minimally invasive techniques into the desired site, delivering osteoconductive demineralized bone fibers with osteoinductive potential to stimulate new bone formation for long term structural stability.
SmartBreast™ Acquires Molecular Breast Imaging Assets from Dilon Technologies®
News provided by
Share this article
PITTSBURGH, Dec. 29, 2020 /PRNewswire/
Smart Breast Corporation (SmartBreast™), a privately held company focused on breast cancer screening and detection, announced today that it has acquired certain Molecular Breast Imaging (MBI) assets from Dilon Technologies, Inc. (Dilon) for an undisclosed amount.
Dilon D6800 MBI scanner acquired by SmartBreast.
Comparison of mammogram in dense breast tissue that appeared “normal” and the MBI scan which detects a hidden early stage invasive cancer (courtesy of Mayo Clinic).
The acquired MBI technology sees through dense breast tissue to find 3 to 4 times more cancers than mammography alone.
TheraCell Announces Delivery Of Over 25,000 Of Its Licensed Bone Fiber Grafts
Products Have Reached an Annual End Customer Sales Rate Approaching $30M
News provided by
Share this article
Share this article
LOS ANGELES, Dec. 17, 2020 /PRNewswire/ TheraCell Inc., a leading allograft solution company, today announced that over 25,000 of its licensed demineralized bone fiber products have been delivered by its licensee partners. TheraCell s partners have seen steady double-digit quarter over quarter growth, now representing an annual end customer sales rate approaching $30M.
(PRNewsfoto/TheraCell, Inc.)
TheraCell has licensed the base fiber technology to AlloSource to produce and market AlloFuse® Cortical Fibers and AlloFuse® Fiber Boats, and to produce private label products to be marketed by other orthopedic companies. The technology has also been licensed to Australian Biotechnologies to produce and market AlloVance® Xpress Fibres, AlloVance® Xpress Hybrid, AlloVance®